The Emerging Role of Atypical Antipsychotics in the Treatment of Tardive Dyskinesia Induced by Other Atypical Antipsychotics
J Clin Psychiatry 2011;72(7):1016 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Letter to the Editor
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
We read with great interest the article by Chan et al comparing the efficacy of risperidone and olanzapine in schizophrenic patients with tardive dyskinesia on treatment with first-generation antipsychotics. The authors of the study concluded that both medications led to significant improvement in dyskinesia scores; however, a statistically significantly greater change was seen in the risperidone group compared with the olanzapine group (P = .0001).
We believe this study raises important questions concerning the role of atypical antipsychotics in the generation and treatment of tardive dyskinesia.